LOW INTERSTITIAL LUNG DISEASE EVENT RATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED POST HOC ANALYSIS OF DATA FROM THE TOFACITINIB CLINICAL DEVELOPMENT PROGRAM

被引：0
|
作者：
Citera, Gustavo [1 ]
Mysler, Eduardo [2 ]
Madariaga, Hugo [3 ]
Cardiel, Mario H. [4 ]
Castaneda, Oswaldo [5 ]
Fischer, Aryeh [6 ]
Richette, Pascal [7 ]
Chartrand, Sandra [8 ]
Park, Jin Kyun [9 ]
Strengholt, Sander [10 ]
Luis Rivas, Jose [11 ]
Thorat, Amit [12 ]
Girard, Tanya [13 ]
Kwok, Kenneth [14 ]
Wang, Lisy [15 ]
Ponce de Leon, Dario [16 ]
机构：
[1] Inst Rehabil Psicofis, Buenos Aires, DF, Argentina
[2] Org Med Invest, Buenos Aires, DF, Argentina
[3] Clin Sur, Arequipa, Peru
[4] Ctr Invest Clin Morelia, Morelia, Michoacan, Mexico
[5] Clin Anglo Amer, Lima, Peru
[6] Univ Colorado Denver, Dept Med, Denver, CO USA
[7] Hop Lariboisiere, AP HP, Dept Rheumatol, Paris, France
[8] Univ Montreal, Hop Maisonneuve Rosemont, Dept Med, Montreal, PQ, Canada
[9] Seoul Natl Univ Hosp, Dept Internal Med, Div Rheumatol, Seoul, South Korea
[10] Pfizer Inc, Capelle Aan Den Ijssel, Netherlands
[11] Pfizer SLU, Madrid, Spain
[12] Pfizer Ltd, Mumbai, Maharashtra, India
[13] Pfizer Inc, Montreal, PQ, Canada
[14] Pfizer Inc, New York, NY USA
[15] Pfizer Inc, Groton, CT 06340 USA
[16] Pfizer Inc, Lima, Peru
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
88
引用
收藏
页码：S42 / S42
页数：1
相关论文
共 50 条
  • [1] Low Interstitial Lung Disease Event Rate in Patients with Rheumatoid Arthritis: Pooled Post Hoc Analysis of Data from the Tofacitinib Clinical Development Program
    Citera, Gustavo
    Mysler, Eduardo
    Madariaga, Hugo
    Cardiel, Mario H.
    Castaneda, Oswaldo
    Fischer, Aryeh
    Richette, Pascal
    Chartrand, Sandra
    Park, Jin Kyun
    Strengholt, Sander
    Rivas, Jose L.
    Thorat, Amit
    Girard, Tanya
    Kwok, Kenneth
    Wang, Lisy
    Ponce de Leon, Dario
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [2] Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients Post Hoc Analysis From 21 Clinical Trials
    Citera, Gustavo
    Mysler, Eduardo
    Madariaga, Hugo
    Cardiel, Mario H.
    Castaneda, Oswaldo
    Fischer, Aryeh
    Richette, Pascal
    Chartrand, Sandra
    Park, Jin Kyun
    Strengholt, Sander
    Rivas, Jose L.
    Thorat, Amit V.
    Girard, Tanya
    Kwok, Kenneth
    Wang, Lisy
    Ponce de Leon, Dario
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 (08) : E482 - E490
  • [3] INCIDENCE RATES OF INTERSTITIAL LUNG DISEASE AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT: A POST HOC POOLED ANALYSIS FROM A COMPENDIUM OF CLINICAL TRIALS
    Dieude, P.
    Sparks, J.
    Fischer, A.
    Chen, L.
    Lozenski, K.
    Dahan, S.
    Chaballa, M.
    Little, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 843 - 843
  • [4] INTERSTITIAL LUNG DISEASE IMPROVEMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND TOFACITINIB
    Madariaga Charaja, Hugo Javier
    Elena Luza, Maria
    Ponce de Leon, Dario
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S48 - S48
  • [5] INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB
    Vanesa Bejarano, Marisel
    Natalia Tamborenea, Maria
    Goni, Mario
    Saldarriaga, Lina
    Pisoni, Cecilia
    Garcia Salinas, Rodrigo
    Salcedo, Mariana
    Helling, Claudia
    Salas, Adrian
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 12 - 13
  • [6] INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB
    Bejarano, Marisel
    Natalia Tamborenea, Maria
    Alberto Goni, Mario
    Saldarriaga, Lina
    Pisoni, Cecilia
    Garcia Salinas, Rodrigo
    Salcedo, Mariana
    Helling, Claudia
    Salas, Adrian
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1672 - 1672
  • [7] Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials
    Wright, Grace C.
    Mysler, Eduardo
    Kwok, Kenneth
    Cadatal, Mary Jane
    Germino, Rebecca
    Yndestad, Arne
    Kinch, Cassandra D.
    Ogdie, Alexis
    RHEUMATOLOGY AND THERAPY, 2024, 11 (05) : 1135 - 1164
  • [8] Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data
    Lee, Eun Bong
    Yamanaka, Hisashi
    Liu, Yi
    Tsai, Wen-Chan
    Chen, Connie
    Kwok, Kenneth
    Yoo, Hyun-Jeong
    Llamado, Lyndon J.
    Wang, Lisy
    Luo, Yingchun
    Sugiyama, Naonobu
    Tanaka, Yoshiya
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (06) : 1094 - 1106
  • [9] Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Yamaoka, Kunihiro
    Arai, Shoko
    Toyoizumi, Shigeyuki
    DeMasi, Ryan
    Fukuma, Yuri
    Hirose, Tomohiro
    Sugiyama, Naonobu
    Zwillich, Samuel H.
    Tanaka, Yoshiya
    MODERN RHEUMATOLOGY, 2019, 29 (05) : 756 - 766
  • [10] Clinical Course of Interstitial Lung Disease in Patients With Rheumatoid Arthritis
    Matteson, Eric L.
    Bendstrup, Elisabeth
    Strek, Mary E.
    Dieude, Philippe
    ACR OPEN RHEUMATOLOGY, 2024, 6 (12) : 836 - 845
12345